info@mdrevenuegroup.com9:00 AM - 5:00 PM | Mon - Fri
MD Revenue Group provides specialized, high-performance revenue cycle management for independent hematology practices, multi-physician blood disorder groups, and specialized infusion centers. We eliminate "Capital Erosion" by mastering the complex 2026 shifts in high-cost clotting factor units, bone marrow biopsy bundling logic, and the high-complexity documentation required for therapeutic phlebotomy and immunotherapy. Our Medical Billing Services are engineered to transform your hematology practice from a high-liability medication purchaser into a proactive capital recovery engine.
Claim Free Hematology AuditFor an independent hematologist, the choice to outsource RCM isn't about giving up control—it's about gaining technical leverage against aggressive payers who want to default your work to "Invoice Cost." Our Medical Billing Services provide the administrative backbone required to allow your hematologists to focus on patient outcomes rather than insurance friction.
As you add new physicians, specialized mid-levels, or specialized coagulation technicians, your billing scales instantly without the need for additional Credentialing staff or office space.
By catching technical and mathematical errors (like Payer Enrollment gaps or expired facility links) *before* submission, we dramatically accelerate your cash flow for clinical growth.
We build "Audit-Armor" into the foundation of your hematology practice. Our experts ensure that every infusion log, every drug waste record, and every phlebotomy note is "Ready for Scrutiny" before it ever leaves your office.
Hematology is a specialty defined by extreme financial risk and the administrative burden of managing medications that can cost upwards of $20,000 per dose. In 2026, the administrative friction for blood-factor therapies and advanced immunotherapies has reached an all-time high, with payers using advanced AI-algorithms to audit "Unit-Level" precision and "Diagnostic-to-Treatment" logic.
A primary source of revenue erosion for hematology practices is the failure to perfectly synchronize the units of clotting factor administered (J7170–J7211) with the HCPCS units allowed by the payer’s specific medical policy. In 2026, if the units don't match the "Volume-to-Dose" calculation in the clinical chart, the claim is auto-denied or downcoded. We implement Revenue Integrity protocols to ensure every milligram of high-cost factor is captured.
Procedures like bone marrow aspiration and biopsy (38220–38221) are frequent targets for 2026 bundling audits. Most generalist billers fail to use the correct "Integrated" code (38222) when both are performed through the same incision, leading to automatic technical denials by payer AI-algorithms. MDRG’s Revenue Cycle Management experts specialize in "Surgical-Grade" coding to avoid these systematic losses.
Therapeutic phlebotomy (99195) for conditions like Polycythemia Vera or Hemochromatosis requires absolute precision in documenting the pre-procedure and post-procedure lab values (Hematocrit/Ferritin). In 2026, payers require a documented "Failure of Conservative Care" or specific threshold values before authorizing payment. MDRG manages the "Diagnostic-to-Billing" correlation to provide 100% reimbursement success.
Topical authority in hematology RCM involves mastering the 38000-series CPT codes and the nuances of high-complexity drug delivery. Our hematology-certified coders ensure every Revenue Cycle Management submission is optimized for technical success.
Biopsy vs. Aspiration bundle logic
Pre/Post lab value documentation
Exact drug-units & time captures
HCPCS unit-to-dosage precision
High-complexity transplant bundling
2026 mandatory waste reporting
Defending evaluation parity
In 2026, hematology billing is a battle of "Clinical Calculation." Payers are no longer just looking for coding errors; they are using AI-driven auditing to challenge the *dosage* and *waste* of high-cost clotting factors. We defend your revenue against these three high-frequency rejection types:
Payer bots often deny entire medication claims if they detect a "Vial Mismatch"—where a single-use vial was billed but no waste (-JW) or zero-waste (-JZ) modifier was applied. In 2026, this is the #1 reason for hematology payment delay.
Many payers have updated their 2026 audit triggers for phlebotomy. If the chart doesn't explicitly state the lab thresholds that triggered the service, the visit is denied as "Routine."
For newer specialized blood disorder drug mappings or advanced monoclonal antibody transitions, payers often trigger "Experimental" denials even for FDA-cleared hardware.
In 2026, the key to hematology revenue is the "Molecular Intensity Narrative." We help your providers implement "Audit-Armor" charting strategies that signal authority to payer algorithms. This includes using "Trigger Phrases" for clotting factor necessity and automating the capture of specialized phlebotomy technical data.
We help you structure your infusion records so that the "Technical Necessity" of a separately identifiable encounter is undeniable to even the most aggressive automated payer bots.
We teach your team how to describe blood disorder progression in a way that reflects the true "Diagnostic Intensity" of the Care, reducing the risk of automated downcoding.
MDRG acts as your practice’s "Blood-System RCM Command Center." We focus entirely on Revenue Cycle Management efficiency so you can focus on clinical diagnostics and patient care.
We synchronize with your EHR (Athena, NextGen, Mod-Med, OncoEMR, etc.) to establish a clean, high-speed data bridge.
Every hematology claim is scrubbed for 2026 CPT/Diagnosis parity before it hits the clearinghouse. We look for "Waste Red-Flags" that AI-payers use to auto-delete high-value clotting factor lines.
We don't accept "No." We challenge every technical surgical and diagnostic denial with clinical precision, leveraging our hematology-certified coders to file high-level appeals for your most complex cases.
Track your net collections, "Per-Visit Acuity Yield," and payer performance points with total transparency via our secure client portal.
To defend your hematology revenue in 2026, your infusion and procedural records must be bulletproof. We provide our hematology clients with a rigorous documentation checklist to ensure compliance:
In a technical audit for a 5-physician independent hematology group in the Southeast, MDRG identified a $172,000 annual revenue leakage in their clotting factor waste (JW) and bone marrow bundling billing. The group was failing to correctly document "Milligram-Level Waste" and was losing the technical value of their 38222 integrated biopsy procedures.
By implementing Revenue Cycle Management best practices—including real-time "Waste-Capture Training" for their clinical staff—MDRG was able to: * **Recover $112,000 in uncaptured drug waste and surgical revenue** within the first 6 months. * **Reduce their "Global-Mismatch" Denial Rate** by 64% using specialized technical narratives. * **Accelerate Cash Flow** by reducing their average days in A/R from 44 days to 23 days.
This hematology group now operates with "Audit-Armor" protection, knowing that every high-value patient hour is protected from automated payer clawbacks.
In the high-stakes environment of 2026, your hematology practice deserves a revenue cycle that is as precise as your clinical care. Don't let your "Clinical Capital" be eroded by primitive billing and administrative friction.
Direct PDF download. We respect medical practice privacy.
Get a free audit of your billing. If we don't find money you're leaving on the table, you don't pay a dime.
